RE:RE:RE:RE:RE:Quick Summary Go and see the movie My cousin Vinny, there is a scene the defendants' lawyer's response to the prosecutor's pitch was "everything he said was bull sh.... That's Scarlett guy's response to most of your posts.
jfm1330 wrote: This is the proof this scarlett guy does not understand much about TH1902 vs docetaxel alone. What he wrote there is plain false, and on top of it, you need the proof of concept to talk about any concentrating effect in human with TH1902, which we don't know if they have it. Preclinical results are irrelevant at this point, because in preclinical they achieved three times the MTD of docetaxel alone and in humans it will be 1.3 times, at best. We are not even sure of that yet. Last summer, Marsolais said that they were expecting to replicate the MTD results they saw on animal models.The least we can say, is that he was way too optimistic on that.
Wino115 wrote: I think there's a chart in one of their poster presentations showing how concentrated the drug was versus standard taxol in one of the tumor types. They did it for various ones and stated something like it was 4-7x more concentrated. Don't quote me, and I'd have to go find it, but there's a few mentions of it in their research documents.
scarlet1967 wrote: TH1902 conjugates two docetaxel molecules as per preclinical results a quarter of the PDC would equal same concentration of docetaxel alone once internalized doing the math you end up
with 10 or more intra cellular concentration. JayjayUSA12007 wrote: Thanks for the summary:
How do you come up with this statement:"It seems the MTD will be at 300mg/m2 which is about 10 times more intracellular concentration of the docetaxel alone" ?
As 300 mg/m2 is about 1.5x the normal docetaxel treatment standard of care, if use this dose results in 10 times more intracellular concentration then SORT+ technology was proven. Is it your understanding as well ?